Home
/ Vazyme
/ Competitors

Vazyme Competitors and Similar CompaniesClear all

Vazyme's competitors and similar companies include Compugen, SiteOne Therapeutics, Inflazome and Diagnostics Biochem Canada.

	Vazyme Nanjing Vazyme Biotech (南京诺唯赞生物科技股份有限公司) is a biotechnology company that provides enzymes and antibodies solutions.	Compugen Compugen is a drug and diagnostic discovery company.	SiteOne Therapeutics SiteOne Therapeutics is a company that develops therapeutics for the treatment of hypersensitivity disorders.	Inflazome Inflazome engages in developing orally available drugs to address clinical unmet needs in inflammatory diseases by targeting the inflammasome.	Diagnostics Biochem Canada DBC Diagnostics Biochem Canada develops and markets quality radioimmunoassay kits and reagents.
Founding Date	Founding Date 2012	Founding Date 1993	Founding Date 2014	Founding Date 2016	Founding Date 1973
Type	Type Public	Type Public	Type Private	Type Subsidiary	Type Private
Tags	Tags Healthcare biotech drug development healthtech medical diagnostics	Tags Healthcare drug development healthtech medical diagnostics	Tags Healthcare biotech drug development medical diagnostics	Tags Healthcare biotech drug development medical diagnostics	Tags Healthcare 3d printing biotech drug development healthtech medical diagnostics
Locations	Locations Nanjing, CN HQ Melbourne, AU Vancouver, CA Nanjing, CN Düsseldorf, DE Hong Kong, HK Budapest, HU see more	Locations Holon, IL HQ South San Francisco, US	Locations San Francisco, US HQ Bozeman, US	Locations Dublin 2, IE HQ Brisbane City, AU Cambridge, GB	Locations London, CA HQ
Employees	Employees 2,867	Employees 74	Employees 2216% increase	Employees 156% decrease	Employees N/A
Valuation ($)	Valuation ($) 1.3 b	Valuation ($) N/A	Valuation ($) 75 m	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) ¥1.4b (FY, 2025)	Revenue (est.) $72.8m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods ¥419.7m (FY, 2025)	Cost of goods $9.3m (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit ¥949.9m (FY, 2025)	Gross profit $63.5m (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit N/A
Net income	Net income (¥22.5m) (FY, 2025)	Net income $35.3m (FY, 2025)	Net income N/A	Net income N/A	Net income N/A
Funding
Total funding raised	Total funding raised $ 78m	Total funding raised N/A	Total funding raised $ 17.8m	Total funding raised $ 17m	Total funding raised N/A